Indian firm plans more contract manufacturing space

By Kirsty Barnes

- Last updated on GMT

Related tags Pharmacology

A new Special Economic Zone (SEZ) is being created by Indian firm
JB Chemicals & Pharmaceuticals for the contract manufacturing
of active pharmaceutical ingredients (APIs), intermediates and
finished drug formulations.

The decision comes at a time when India's drug manufacturing industry is tipped to grow 10 per cent over the next three years as more pharma firms shift some or all of their manufacturing operations there to cut costs.

The new facilities will be constructed over 130 hectares at Panoli, Gujarat, and it is planned that they will become operational during 2009, said the firm.

With an investment of Rs 115 crore (€19m), the new processing area will consist of 10-15 industrial units belonging to both Indian and foreign pharmaceutical companies in addition to JB Chemical's own units.

As well as contract manufacturing, the new facilities will also undertake in-house manufacturing.

JB Chemicals already has two US Food and Drug Administration (FDA)-approved facilities in the area - a bulk drug unit and a formulation unit - that manufacture the firm's own drug products.

It is estimated that the new industrial units, with a direct investment of over Rs 800 crore, will generate 6,000 new jobs as well as the indirect employment of 15,000 people.

Since 2000 the Indian government has been establishing various SEZs in order to boost exports in local regions across a number of industries, including pharmaceuticals.

The benefits offered by the latest SEZ proposed by JB Chemicals would give "a significant further boost to exports,"​ the company said.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

PBPK modeling that saves you time and money

PBPK modeling that saves you time and money

Content provided by Lonza Small Molecules | 09-Oct-2023 | White Paper

Understanding pharmacokinetic behaviors ahead of later-stage development means making informed decisions earlier. This enhanced capability helps your drug...

Related suppliers

Follow us

Products

View more

Webinars